Tirzepatide
A dual GIP and GLP-1 receptor agonist — the active ingredient in Zepbound and Mounjaro — with the largest trial averages in the class.
Tirzepatide activates two incretin receptors at once: GLP-1, which curbs appetite and slows digestion, and GIP, which influences how the body handles and stores energy. That dual mechanism produced the headline numbers of the GLP-1 era — in SURMOUNT-1, the 15 mg dose averaged 22.5% body-weight loss over 72 weeks (efficacy estimand), with 57% of participants losing 20% or more.
It is sold as Zepbound, FDA-approved for chronic weight management, and Mounjaro, approved for type 2 diabetes — both once-weekly injections, with no tablet form available. Tirzepatide suits patients chasing maximum trial-average percentage who are comfortable with weekly self-injection; our tirzepatide program starts at $299/month with the brand matched by the prescribing doctor.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Tirzepatide? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment